Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
शेयरों में रैंक #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
शेयर मूल्य
$58.70
अंतिम समन्वयन: 2024-01-23
मार्केट कैप
$2.98B
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
0.00%
देश
US
व्यापार Mirati Therapeutics, Inc. (MRTX)

श्रेणी

Mirati Therapeutics, Inc. (MRTX) के लिए EPS
2026 TTM तक का EPS: 0
Mirati Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) 0 है। 2026 के अंत में, कंपनी का EPS 0 था, जो 2026 के EPS 0 के के बराबर था।
Mirati Therapeutics, Inc. के लिए 2026 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
वर्ष EPS परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
कंपनी EPS EPS अंतर देश
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH